Integra LifeSciences Holdings Corporation (IART) P/E Ratio History
Historical price-to-earnings valuation from 2001 to 2024
Loading P/E history...
IART Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Integra LifeSciences Holdings Corporation (IART) trades at a price-to-earnings ratio of -2.0x, with a stock price of $13.56 and trailing twelve-month earnings per share of $-6.44.
The current P/E is 104% below its 5-year average of 51.7x. Over the past five years, IART's P/E has ranged from a low of 20.6x to a high of 144.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, IART trades at a 109% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, IART trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IART DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IART P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $17B | 30.5 | - | -25% | |
| $4B | 29.3 | - | +5% | |
| $2B | 42.8 | 2.21 | +31% | |
| $12B | 21.7 | 0.70Best | +423%Best | |
| $2B | 168.5 | - | +166% | |
| $3B | 15.0Lowest | - | +382% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
IART Historical P/E Data (2001–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $29.14 | $0.29 | 101.3x | +43% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $35.45 | $0.50 | 71.0x | -0% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $43.55 | $0.83 | 52.4x | -26% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $38.19 | $1.21 | 31.5x | -56% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $41.13 | $1.57 | 26.2x | -63% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $57.41 | $2.06 | 27.9x | -61% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $56.07 | $2.16 | 26.0x | -63% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $42.36 | $2.06 | 20.6x | -71% |
| FY2022 Q2 | $54.03 | $1.97 | 27.4x | -61% | |
| FY2022 Q1 | $64.26 | $1.84 | 34.9x | -51% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $66.99 | $1.98 | 33.8x | -52% |
| FY2021 Q3 | $68.48 | $2.54 | 27.0x | -62% |
Average P/E for displayed period: 71.0x
See IART's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IART Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IART vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIART — Frequently Asked Questions
Quick answers to the most common questions about buying IART stock.
Is IART stock overvalued or undervalued?
IART trades at -2.0x P/E, below its 5-year average of 51.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does IART's valuation compare to peers?
Integra LifeSciences Holdings Corporation P/E of -2.0x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is IART's PEG ratio?
IART PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2001-2024.